0001415889-25-005704.txt : 20250226 0001415889-25-005704.hdr.sgml : 20250226 20250226173033 ACCESSION NUMBER: 0001415889-25-005704 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250224 FILED AS OF DATE: 20250226 DATE AS OF CHANGE: 20250226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Macrae Sandy CENTRAL INDEX KEY: 0001675687 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 25671608 MAIL ADDRESS: STREET 1: 721 ST. GEORGES ROAD CITY: PHILADELPHIA STATE: PA ZIP: 19119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94084 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94084 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 form4-02262025_100229.xml X0508 4 2025-02-24 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001675687 Macrae Sandy C/O SANGAMO THERAPEUTICS, INC. 501 CANAL BLVD. RICHMOND CA 94084 true true false false PRESIDENT, CEO AND DIRECTOR 0 Common Stock 2025-02-24 4 F 0 7488 1 D 2088511 D Common Stock 2025-02-25 4 F 0 10663 0.9561 D 2077848 D Common Stock 2025-02-25 4 A 0 375000 0 A 2452848 D Stock Option (Right to Buy) 0.9561 2025-02-25 4 A 0 1750000 0 A 2035-02-24 Common Stock 1750000 1750000 D Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. Includes: (a) 7,259 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 58,988 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 21,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final quarterly installment on February 25, 2025 and (c) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. Includes: (a) 10,337 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Includes: (a) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. /s/ Prathyusha Duraibabu, Attorney-in-Fact 2025-02-26